Vitamin D –binding protein
AltitudeomicsDB
Protein Official symbol |
GC |
Aliases |
GC |
Chromosomal Location |
4 |
Length |
474 |
Uniprot ID |
P02774 |
EC number |
None |
Protein family Information(Pfam) |
PF00273;PF09164; |
PDB id |
1J78;1J7E;1KW2;1KXP;1LOT;1MA9; |
InterPro ID |
IPR000264;IPR020858;IPR020857;IPR014760;IPR000213;IPR015247; |
dbSNP |
rs7041 rs4588 rs9016 |
AltitudeomicsDB
Protein 1 |
Protein 2 |
Combine Score |
CUBN |
LRP2 |
0.996 |
GC |
LRP2 |
0.972 |
GC |
CUBN |
0.966 |
LGMN |
CUBN |
0.914 |
GC |
LGMN |
0.904 |
VDR |
GC |
0.904 |
GC |
AHSG |
0.903 |
Gene Ontology Semantic Similarity
Download Tab separated file
# |
8029 (CUBN) |
2638 (GC) |
5641 (LGMN) |
7421 (VDR) |
4036 (LRP2) |
197 (AHSG) |
8029 (CUBN)
|
1.00
|
0.39
|
0.21
|
0.49
|
0.70
|
0.16
|
2638 (GC)
|
0.39
|
1.00
|
0.11
|
0.47
|
0.35
|
0.09
|
5641 (LGMN)
|
0.21
|
0.11
|
1.00
|
0.14
|
0.17
|
0.11
|
7421 (VDR)
|
0.49
|
0.47
|
0.14
|
1.00
|
0.41
|
0.11
|
4036 (LRP2)
|
0.70
|
0.35
|
0.17
|
0.41
|
1.00
|
0.13
|
197 (AHSG)
|
0.16
|
0.09
|
0.11
|
0.11
|
0.13
|
1.00
|
Association with High Altitude
Protein Official symbol |
Source Organism |
Tissue of Expression |
Level of hypoxia |
Altitude |
Duration of experiment |
Level of expression |
Fold change |
Experiment details |
geographical location |
ethnicity of the patients |
Control group |
Control (Fold change) |
Reference (PMID) |
GC |
Human |
Blood |
- |
3600 m |
Native |
upregulated |
- |
TMT-based proteomic analysis/LC-MS |
Central Asia |
Tibetans |
- |
High altitude native vs. low Lander |
30908922 |
GC |
Human |
Blood |
- |
3600 m |
Native |
upregulated |
- |
TMT-based proteomic analysis/LC-MS |
Central Asia |
Tibetans |
- |
High altitude native vs. low Lander |
30908922 |
GC |
Human |
Plasma |
- |
3500-4000m |
Native |
upregulated |
1.78 |
2-DE |
Northern indo-australian plate |
Ladakhi |
1 |
Sea level healthy individuals |
23844025 |
Association with TF
TF |
TF Entrez |
Gene |
Gene Entrez |
Type |
PMID |
Database |
TP53 |
7157 |
GC |
2638 |
Activation |
12556536 |
TRUSST |
Association with miRNA
miRTarBase ID |
miRNA |
Species (miRNA) |
Protein Official Symbol |
Human Entrez ID |
Species (Target Gene) |
Experiments |
Support Type |
References (PMID) |
MIRT016788 |
hsa-miR-335-5p |
Homo sapiens |
GC |
2638 |
Homo sapiens |
Microarray |
Functional MTI (Weak) |
18185580 |
Gene Ontology
ID |
GO ID |
GO Term |
GO Type |
2638 |
GO:0042359 |
vitamin D metabolic process |
GOTERM_BP_DIRECT |
2638 |
GO:1902118 |
acyl-L-homoserine-lactone lactonohydrolase activity |
GOTERM_MF_DIRECT |
2638 |
GO:0051180 |
vitamin transport |
GOTERM_BP_DIRECT |
2638 |
GO:0043202 |
lysosomal lumen |
GOTERM_CC_DIRECT |
2638 |
GO:0070062 |
extracellular exosome |
GOTERM_CC_DIRECT |
2638 |
GO:0051183 |
ATPase binding |
GOTERM_MF_DIRECT |
2638 |
GO:0005829 |
cytosol |
GOTERM_CC_DIRECT |
2638 |
GO:0003779 |
microtubule motor activity |
GOTERM_MF_DIRECT |
2638 |
GO:0005499 |
sodium:potassium-exchanging ATPase activity |
GOTERM_MF_DIRECT |
2638 |
GO:0005576 |
extracellular region |
GOTERM_CC_DIRECT |
2638 |
GO:0005615 |
extracellular space |
GOTERM_CC_DIRECT |
2638 |
GO:0072562 |
blood microparticle |
GOTERM_CC_DIRECT |
Pathways
Human Entrez ID |
KEGG ID |
KEGG Term |
Association with Disease
Protein Official Symbol |
Human Entrez ID |
Disease Name |
Disease Id |
Disease Semantic Type |
Semantic score |
DSI |
DPI |
Disease Type |
GC |
2638 |
Liver Cirrhosis |
C0023890 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Graves Disease |
C0018213 |
Disease or Syndrome |
0.32 |
0.525 |
0.793 |
disease |
GC |
2638 |
Injury wounds |
C0043250 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Wounds and Injuries |
C0043251 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Hepatic Coma |
C0019147 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Adverse reaction to drug |
C0041755 |
Pathologic Function |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Multiple Sclerosis |
C0026769 |
Disease or Syndrome |
0.32 |
0.525 |
0.793 |
disease |
GC |
2638 |
Hepatic Stupor |
C0751198 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Drug toxicity |
C0013221 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Endotoxic shock |
C0036981 |
Pathologic Function |
0.3 |
0.525 |
0.793 |
phenotype |
GC |
2638 |
Liver Cirrhosis, Experimental |
C0023893 |
Experimental Model of Disease |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Kidney Failure, Acute |
C0022660 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Schizophrenia |
C0036341 |
Mental or Behavioral Dysfunction |
0.31 |
0.525 |
0.793 |
disease |
GC |
2638 |
Septic Shock |
C0036983 |
Pathologic Function |
0.3 |
0.525 |
0.793 |
phenotype |
GC |
2638 |
Drug-Induced Liver Disease |
C0860207 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Osteopenia |
C0029453 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Multiple Sclerosis, Acute Fulminating |
C0751324 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Hepatic Encephalopathy |
C0019151 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Rheumatoid Arthritis |
C0003873 |
Disease or Syndrome |
0.32 |
0.525 |
0.793 |
disease |
GC |
2638 |
Metabolic Bone Disorder |
C0005944 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Fibrosis, Liver |
C0239946 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Toxic Shock Syndrome |
C0600327 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Hepatitis, Toxic |
C0019193 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Liver Failure, Acute |
C0162557 |
Disease or Syndrome |
0.32 |
0.525 |
0.793 |
disease |
GC |
2638 |
Fulminant Hepatic Failure with Cerebral Edema |
C0751197 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Lung Neoplasms |
C0024121 |
Neoplastic Process |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Malignant neoplasm of lung |
C0242379 |
Neoplastic Process |
0.31 |
0.525 |
0.793 |
disease |
GC |
2638 |
Hepatitis, Drug-Induced |
C1262760 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Drug-Induced Acute Liver Injury |
C3658290 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Acute kidney injury |
C2609414 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Chemically-Induced Liver Toxicity |
C4279912 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Traumatic injury |
C3263723 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Acute Kidney Insufficiency |
C1565662 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
GC |
2638 |
Research-Related Injuries |
C4046002 |
Injury or Poisoning |
0.3 |
0.525 |
0.793 |
group |
GC |
2638 |
Chemical and Drug Induced Liver Injury |
C4277682 |
Disease or Syndrome |
0.3 |
0.525 |
0.793 |
disease |
Association with Drug
Protein Official Symbol |
Human Entrez ID |
drug_claim_primary_name |
drug_name |
drug_chembl_id |
interaction_types |
GC |
2638 |
AFEGOSTAT TARTRATE |
AFEGOSTAT TARTRATE |
CHEMBL2105671 |
None |
GC |
2638 |
ANISINDIONE |
ANISINDIONE |
CHEMBL712 |
inhibitor |
GC |
2638 |
ASA |
ASPIRIN |
CHEMBL25 |
None |
GC |
2638 |
VITAMIN D |
None |
None |
None |